Atossa Therapeutics issues letter to shareholders

Atossa Therapeutics (ATOS) announced that Steven Quay, M.D., Ph.D., Chairman and CEO, has issued a Letter to Shareholders providing an update on the Company’s clinical programs and recent events. The full text of the letter follows: “As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment. Last year was vital for Atossa as we continued to demonstrate the broad utility of (Z)-endoxifen as an innovative therapy that has the potential to transform the breast cancer treatment landscape… As we enter 2025, we are excited to build on this momentum. Our focus remains on: Identifying key opportunities to advance (Z)-endoxifen into registrational clinical trials with the goal of advancing (Z)-endoxifen to the market in the quickest way possible… Amplifying our ongoing business development efforts to ensure women globally have the opportunity to benefit from (Z)-endoxifen. Deepening collaborations with industry leaders and advocacy groups to broaden the impact of our work. Extending our track record of financial strength that will position us to support our long-term growth.”